ChromaDex FY2025 EPS Forecast Increased by HC Wainwright

ChromaDex Co. (NASDAQ:CDXC) – Research analysts at HC Wainwright boosted their FY2025 earnings estimates for shares of ChromaDex in a research report issued on Monday, November 4th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $0.21 per share for the year, up from their previous forecast of $0.12. HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for ChromaDex’s current full-year earnings is $0.02 per share.

Separately, Roth Mkm boosted their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday.

ChromaDex Stock Performance

Shares of ChromaDex stock opened at $6.77 on Wednesday. The firm has a 50-day moving average of $3.77 and a 200-day moving average of $3.31. ChromaDex has a 52-week low of $1.32 and a 52-week high of $7.08. The stock has a market cap of $517.09 million, a PE ratio of 677.68 and a beta of 1.88.

ChromaDex (NASDAQ:CDXC) last released its quarterly earnings results on Thursday, October 31st. The company reported $0.02 earnings per share for the quarter. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. The business had revenue of $25.58 million during the quarter, compared to analysts’ expectations of $23.70 million. During the same period last year, the firm posted ($0.01) EPS.

Insider Buying and Selling

In other ChromaDex news, Director Kristin Patrick sold 23,000 shares of the stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $3.57, for a total transaction of $82,110.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 9.64% of the stock is owned by company insiders.

Hedge Funds Weigh In On ChromaDex

Several hedge funds and other institutional investors have recently modified their holdings of the business. OneDigital Investment Advisors LLC boosted its stake in ChromaDex by 5.5% in the third quarter. OneDigital Investment Advisors LLC now owns 59,414 shares of the company’s stock valued at $217,000 after buying an additional 3,097 shares in the last quarter. BSW Wealth Partners acquired a new position in ChromaDex during the 3rd quarter worth approximately $324,000. SG Americas Securities LLC bought a new position in ChromaDex in the 3rd quarter valued at approximately $61,000. The Manufacturers Life Insurance Company acquired a new position in shares of ChromaDex during the second quarter worth $31,000. Finally, Marshall Wace LLP acquired a new stake in shares of ChromaDex during the 2nd quarter valued at $56,000. Institutional investors own 15.41% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.